Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Gastric Cancer
•
Esophageal Cancer
•
Medical Oncology
•
Gastroesophageal Cancer
How do you manage postoperative residual disease after neoadjuvant chemoradiotherapy and surgery for a patient with locally advanced esophageal or GE junction adenocarcinoma?
Related Questions
Would you consider Trastuzumab Deruxtecan as a second line option for metastatic HER2+ squamous cell carcinoma of the esophagus after progression on FOLFOX + Nivolumab?
How would you approach treating a patient who refuses surgery, but has significant residual disease after chemoradiotherapy for squamous cell carcinoma of the esophagus?
Would you consider a D2 gastrectomy in young fit patients with gastric adenocarcinoma and positive peritoneal cytology without macroscopic disease if cytology turned negative after neoadjuvant chemotherapy?
For a patient who has T4 squamous cell esophageal carcinoma on imaging, and who has biopsy-confirmed disease in an involved local lymph node, are EUS or EGD still indicated to complete workup?
In a patient with a mid-esophageal squamous cell carcinoma with tracheal invasion confirmed on bronchoscopy, would you treat with definitive chemo-radiation with curative intent?
Would you use triplet chemotherapy FLOT in lieu of chemoRT for patients with localized esophageal squamous cell carcinoma?
Would you treat elderly patients with early-stage gastric cancer with perioperative FOLFOX or FLO (FLOT without T)?
Which chemotherapy would you recommend for concurrent use with radiation in a patient with localized esophageal adenocarcinoma who has severe Charcot-Marie-Tooth disease?
For a patient with T3N1M0 esophageal adenocarcinoma, who suffered esophageal perforation necessitating metallic stent placement, would you favor a neoadjuvant chemoradiation or perioperative chemotherapy approach?
Which patients with localized esophageal adenocarcinoma, if any, would you offer nivolumab after lack of pCR to neoadjuvant FLOT?
